| Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients JL Hay, JM White, F Bochner, AA Somogyi, TJ Semple, B Rounsefell The Journal of Pain 10 (3), 316-322, 2009 | 216 | 2009 |
| Measuring blood–brain barrier penetration using the NeuroCart, a CNS test battery GJ Groeneveld, JL Hay, JM Van Gerven Drug Discovery Today: Technologies 20, 27-34, 2016 | 67 | 2016 |
| Advanced methods for dose and regimen finding during drug development: summary of the EMA/EFPIA workshop on dose finding (London 4–5 December 2014) FT Musuamba, E Manolis, N Holford, SYA Cheung, LE Friberg, ... CPT: pharmacometrics & systems pharmacology 6 (7), 418-429, 2017 | 65 | 2017 |
| Respiratory effects of the nociceptin/orphanin FQ peptide and opioid receptor agonist, cebranopadol, in healthy human volunteers A Dahan, M Boom, E Sarton, J Hay, GJ Groeneveld, M Neukirchen, ... Anesthesiology 126 (4), 697-707, 2017 | 56 | 2017 |
| Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers M Roozekrans, R van der Schrier, P Okkerse, J Hay, JF McLeod, A Dahan Anesthesiology 121 (3), 459-468, 2014 | 49 | 2014 |
| Fentanyl utility function: a risk–benefit composite of pain relief and breathing responses M Boom, E Olofsen, M Neukirchen, R Fussen, J Hay, G Jan Groeneveld, ... Anesthesiology 119 (3), 663-674, 2013 | 47 | 2013 |
| Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects P Hoever, J Hay, M Rad, M Cavallaro, JM van Gerven, J Dingemanse Journal of clinical psychopharmacology 33 (3), 363-370, 2013 | 44 | 2013 |
| Effects of a single, oral 60 mg caffeine dose on attention in healthy adult subjects MMM Wilhelmus, JL Hay, RGJA Zuiker, P Okkerse, C Perdrieu, J Sauser, ... Journal of psychopharmacology 31 (2), 222-232, 2017 | 43 | 2017 |
| Electrocardiogram characteristics of methadone and buprenorphine maintained subjects P Athanasos, AL Farquharson, P Compton, P Psaltis, J Hay Journal of addictive diseases 27 (3), 31-35, 2008 | 41 | 2008 |
| Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial MC Bielsky, A Cook, A Wallington, A Exley, S Kauser, JL Hay, L Both, ... Drug Discovery Today 25 (11), 1910-1918, 2020 | 37 | 2020 |
| Lack of Detection of the Analgesic Properties of PF‐05089771, a Selective Nav1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects P Siebenga, G van Amerongen, JL Hay, A McDonnell, D Gorman, R Butt, ... Clinical and translational science 13 (2), 318-324, 2020 | 37 | 2020 |
| The use of a battery of pain models to detect analgesic properties of compounds: A two‐part four‐way crossover study P Okkerse, G van Amerongen, ML de Kam, J Stevens, RP Butt, R Gurrell, ... British journal of clinical pharmacology 83 (5), 976-990, 2017 | 37 | 2017 |
| A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models G van Amerongen, MW de Boer, GJ Groeneveld, JL Hay British Journal of Clinical Pharmacology 82 (4), 903-922, 2016 | 36 | 2016 |
| The EMA review of mylotarg (gemtuzumab ozogamicin) for the treatment of acute myeloid leukemia S Ali, HM Dunmore, D Karres, JL Hay, T Salmonsson, C Gisselbrecht, ... The Oncologist 24 (5), e171-e179, 2019 | 31 | 2019 |
| Responsiveness of electrical nociceptive detection thresholds to capsaicin (8%)-induced changes in nociceptive processing RJ Doll, G van Amerongen, JL Hay, GJ Groeneveld, PH Veltink, ... Experimental brain research 234, 2505-2514, 2016 | 26 | 2016 |
| Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans G van Amerongen, PS Siebenga, R Gurrell, P Dua, M Whitlock, D Gorman, ... British Journal of Anaesthesia 123 (2), e194-e203, 2019 | 25 | 2019 |
| Determining pain detection and tolerance thresholds using an integrated, multi-modal pain task battery JL Hay, P Okkerse, G van Amerongen, GJ Groeneveld JoVE (Journal of Visualized Experiments), e53800, 2016 | 25 | 2016 |
| Model‐based exposure‐response analysis to quantify age related differences in the response to scopolamine in healthy subjects R Alvarez‐Jimenez, GJ Groeneveld, JMA van Gerven, SC Goulooze, ... British journal of clinical pharmacology 82 (4), 1011-1021, 2016 | 24 | 2016 |
| Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects JL Hay, SF La Vincente, AA Somogyi, CB Chapleo, JM White European Journal of Pain 15 (3), 293-298, 2011 | 24 | 2011 |
| Demonstration of an anti‐hyperalgesic effect of a novel pan‐Trk inhibitor PF‐06273340 in a battery of human evoked pain models P Loudon, P Siebenga, D Gorman, K Gore, P Dua, G van Amerongen, ... British journal of clinical pharmacology 84 (2), 301-309, 2018 | 23 | 2018 |
